Immunoprecise Antibodies Ltd
XTSX:IPA
Immunoprecise Antibodies Ltd
Income from Continuing Operations
Immunoprecise Antibodies Ltd
Income from Continuing Operations Peer Comparison
Competitive Income from Continuing Operations Analysis
Latest Figures & CAGR of Competitors
Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Immunoprecise Antibodies Ltd
XTSX:IPA
|
Income from Continuing Operations
-CA$7.3m
|
CAGR 3-Years
-12%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Abcellera Biologics Inc
NASDAQ:ABCL
|
Income from Continuing Operations
-$146.4m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Arch Biopartners Inc
XTSX:ARCH
|
Income from Continuing Operations
-CA$5.5m
|
CAGR 3-Years
14%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
-39%
|
|
Replicel Life Sciences Inc
XTSX:RP
|
Income from Continuing Operations
-CA$69.3k
|
CAGR 3-Years
69%
|
CAGR 5-Years
51%
|
CAGR 10-Years
N/A
|
|
Innovotech Inc
XTSX:IOT
|
Income from Continuing Operations
-CA$157.6k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-4%
|
CAGR 10-Years
15%
|
See Also
What is Immunoprecise Antibodies Ltd's Income from Continuing Operations?
Income from Continuing Operations
-7.3m
CAD
Based on the financial report for Apr 30, 2021, Immunoprecise Antibodies Ltd's Income from Continuing Operations amounts to -7.3m CAD.
What is Immunoprecise Antibodies Ltd's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 3Y
-12%
Over the last year, the Income from Continuing Operations growth was -48%. The average annual Income from Continuing Operations growth rates for Immunoprecise Antibodies Ltd have been -12% over the past three years .